Merrill puts Alkermes at buy

Alkermes Inc. was rated by Merrill Lynch analyst Hari Sambasivam at buy ahead of the company's quarterly results. Merrill estimates total revenues of $48.5 million, including $10.7 million of Vivitrol-related revenues (end user sales of $5 million), total expenses of $50.8 million and pro forma earnings per share of ($0.04). Shares of the Cambridge, Mass.-based biotechnology company were up 25 cents, or 1.55%, at $16.43. (Nasdaq: ALKS)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.